The firm uses a miniaturized, bead-based-ELISA format to multiplex hundreds to thousands of immunoassays rapidly and without antibody cross-reactivity.
The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.
Researchers identified a handful of microbes associated with spontaneous preterm birth, and highlighted host immune protein levels with potential ties to the condition.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The company's diagnostics business saw 8 percent growth, while its Covance segment retreated 2 percent. The firm lowered its adjusted EPS estimate for the full year.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.
